{"ModuleTitle": "Company Description", "CompanyName": "XTL Biopharmaceuticals Ltd.", "Symbol": "XTLB", "Address": "XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE, NEW YORK, New York, 10016, United States of America", "Phone": "972 9 955 7080", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "Middle East", "CompanyDescription": "We are a biopharmaceutical company engaged in the acquisition and development of\r\npharmaceutical drugs for the treatment of autoimmune diseases. Our current drug\r\ndevelopment program is focused on the development of hCDR1 for the treatment of\r\nSLE and SS.\r\n\r\n \r\n\r\nCompany Information and History\r\n\r\n \r\n\r\nOur legal and commercial name is XTL Biopharmaceuticals Ltd. We were established\r\nas a private company limited by shares under the laws of the State of Israel on\r\nMarch 9, 1993, under the name Xenograft Technologies Ltd. We re-registered as a\r\npublic company on June 7, 1993, in Israel, and changed our name to XTL\r\nBiopharmaceuticals Ltd. on July 3, 1995.\r\n\r\n \r\n\r\nWe commenced operations to use and commercialize technology developed at the\r\nWeizmann Institute, in Rehovot, Israel.\r\n", "KeyExecutives": [{"name": "Daphna Paran", "title": "Medical Director"}, {"name": "Itay Weinstein", "title": "Chief Financial Officer"}, {"name": "Shlomo Spokone Shalev", "title": "Chief Executive Officer & Executive Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}